Cost-Effectiveness of Genetic Screening for Lynch Syndrome
Lee P. Shulman, MD, FACMG, FACOG
The Anna Ross Lapham Professor in Obstetrics and Gynecology, Chief, Division of Clinical Genetics, Co-Director, Northwestern Ovarian Cancer Early Detection, and Prevention Program, Department of Obstetrics and Gynecology, Director, Cancer Genetics Program, Robert H. Lurie Comprehensive Cancer Program, Feinberg School of Medicine of Northwestern University, Adjunct Professor of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago College of Pharmacy
Dr Shulman reports that he is a consultant to Bayer HealthCare Pharmaceuticals, Inc.; Myriad Genetics Laboratories, Inc.; Teva Pharmaceutical Industries Ltd; Genzyme Genetics; and Ferring Pharmaceuticals. He is a speaker for Bayer HealthCare Pharmaceuticals, Inc.; Teva Pharmaceutical Industries Ltd; Merck & Co., Inc.; and GlaxoSmithKline. He receives grant/ research support from Bayer HealthCare Pharmaceuticals, Inc.